Ruben A. Mesa, MD, FACP - Risk-Adapted Treatment Algorithms in Myelofibrosis: Optimizing Patient Outcomes With JAK Inhibitors

Please visit answersincme.com/AJK860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in myeloproliferative neoplasms reviews strategies for optimizing outcomes for patients with myelofibrosis. Upon completion of this activity, participants should be better able to: Recognize treatment goals in the management of patients with myelofibrosis; Outline strategies to assess patient risk, including risk stratification of patients with myelofibrosis; and Review the latest clinical implications of Janus kinase (JAK) inhibitors in the treatment of myelofibrosis.

There are no comments yet.

Please log in to write the first comment.